

Company Review

Dr Nina Webster
CEO & Managing Director




Dimerix

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.


2018/2019 achievements



FY2019 Financial Outcomes

Cash Reserves
at June 2019
\$3.56 million

FY2019 net
operating cash
expenditure
\$2.7m



Corporate snapshot (ASX:DXB)

Financial information

Share price (27Nov19)	A\$0.13
52 week low / high	A\$0.07 / 0.14
Shares on issue	158.8m

Market Capitalisation


Cash (as at 30Sep19)	A\$1.99 million*
Debt (as at 30Sep19)	\$0

Enterprise value

A\$18.6 million

**does not include R&D tax rebate of \$1.2 million received October 2019*

Share price performance



Executive summary

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs using its proprietary platform technology

Three product candidates in active development:

- DMX-200 in two Phase 2 studies:
 1. **Focal Segmental Glomerulosclerosis (FSGS)**
 2. **Diabetic Kidney Disease**
- DMX-700 preparing for clinical studies:
 3. **Chronic Obstructive Pulmonary Disease (COPD)**

Clinical readout
for both studies
in Q2 2020

In clinic within
2 years


Receptor-HIT platform technology:

4. Other potential pipeline candidates under assessment
5. Receptor-HIT assay licensed globally

Potential for more
new pipeline
candidates

A pipeline of drugs identified using Receptor-HIT

Programs based on the critical scientific rationale that GPCRs act as a complex with other GPCRs and have novel pharmacology when in complex





Strategic Fit

- Dimerix is developing a **commercial pipeline** of drugs for G Protein-Coupled Receptors (GPCR) largely targeting chemokine pathway diseases with a **clear unmet need**
- Dimerix can utilise its current core **competencies** and **capabilities** to execute on the disclosed opportunities
- Dimerix has identified **new uses** for existing drugs to drive the **discovery** of new drugs and research programs
- Dimerix has **multiple products** in its pipeline, at different development stages, **diversifying** risk and increasing potential future sources of revenue

Development pipeline

3 product candidates in the pipeline, with 2 clinical read outs expected in 2020





DMX-200 Overview

DMX-200 overview

New Chemical Entity*
Never been FDA
approved

DMX-200: a small molecule known as propagermanium

- Twice daily, oral administration
- Administered to patients already on standard of care treatment


DMX has completed a Phase 1 and a Phase 2a clinical studies in kidney disease, providing clinically and statistically significant results:

- **36% reduction in proteinuria (in addition to the 24% reduction seen with irbesartan)**

Compelling data encouraged Dimerix to progress into 2 Phase 2 clinical studies:

- Phase 2a in Focal Segmental Glomerulosclerosis (FSGS) – an orphan indication
- Phase 2 in Diabetic Kidney Disease

DMX-200 regulatory strategy





DMX-700 Overview

COPD landscape

Global Initiatives

- World Health Organization (WHO)
- COPD Foundation
- American Thoracic Society
- Centers for Disease Control & Prevention (CDC)
- National Institute of Health (NIH)

All working towards raising COPD awareness in the population

2018 – FDA Guidance:

- Significantly shorter clinical trial size and duration required
 - Hard endpoints versus surrogate endpoints
 - Endpoints in weeks not years

Global COPD treatment market US\$14 billion (2017) & projected to increase at CAGR >4% to 2026

Asia Pacific expected to be fastest growing COPD market at CAGR ~8.7%

No candidates in late stage development

COPD is responsible for \$72 billion/year in direct healthcare expenditures in US

No cures available & existing treatments aimed at relieving symptoms only



DMX-700 overview

DMX-700: oral administration candidate:

- Two molecules working together, each with an established safety profile
- Dimerix has completed initial studies on receptors involved in COPD.
- Certain lung cells express multiple receptors, thus blocking only one receptor does not block signalling and results in only a partial response to treatment
- **DMX-700 blocks both receptors simultaneously to provide a complete response to treatment**
- Compelling data encouraged Dimerix to progress candidate towards clinical development

**New Chemical
Entity**
Attracting 5 year
exclusivity

Timeline to clinic
~2 years


Actual molecules &
receptor targets
remain confidential
pending additional
patent submissions



Dimerix

Value Driving
Events

2019/2020 value driving events



DIMERIX

End of Presentation



Dimerix